Comparative Pharmacology
Head-to-head clinical analysis: DECA DURABOLIN versus WINSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECA DURABOLIN versus WINSTROL.
DECA-DURABOLIN vs WINSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nandrolone decanoate is an anabolic steroid that binds to androgen receptors, increasing protein synthesis and promoting muscle growth. It also stimulates erythropoietin production, increasing red blood cell mass.
Winstrol (stanozolol) is an anabolic steroid derived from dihydrotestosterone. It binds to androgen receptors, increasing protein synthesis and inhibiting catabolic glucocorticoid activity, leading to enhanced muscle growth and reduced inflammation.
Intramuscular injection of 100-200 mg every 1-3 weeks for anabolic effects; for replacement therapy, 50-100 mg every 2-4 weeks.
Adults: 2 mg orally three times daily, or 50 mg/mL intramuscularly once monthly (3-4 week intervals) for anabolic effect. Dose range: 1-3 mg/kg/day for hereditary angioedema.
None Documented
None Documented
Terminal half-life of nandrolone decanoate is 4.3 hours for the decanoate ester, but the active metabolite nandrolone has a prolonged half-life of 6-7 days due to slow release from intramuscular depot and enterohepatic recirculation; clinical effects persist for 3-4 weeks.
Terminal elimination half-life: 9-10 hours for oral administration (stanozolol); parenteral (IM) half-life extends to ~24 hours due to slow release from injection site. Clinical context: supports once-daily oral dosing or weekly IM dosing.
Primarily renal (90% as metabolites, 5% unchanged); fecal elimination accounts for <5%.
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates) and 10% as unchanged drug; minor biliary/fecal elimination (<5%).
Category C
Category C
Anabolic Steroid
Anabolic Steroid